CCMG
CRL icon

Clark Capital Management Group’s Charles River Laboratories CRL Stock Holding History

Clark Capital Management Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23M Buy
101,462
+14,953
+17% +$2.66M 0.13% 155
2026
Q1 		$14.9M Buy
86,509
+44,118
+104% +$8.18M 0.09% 161
2025
Q4 		$8.46M Buy
+42,391
New +$7.69M 0.05% 181
2023
Q1 		– Sell
-2,884
Closed -$628K – 332
2022
Q4 		$628K Sell
2,884
-135
-4% -$29.5K 0.01% 281
2022
Q3 		$594K Buy
3,019
+71
+2% +$15.3K 0.01% 272
2022
Q2 		$631K Sell
2,948
-102,138
-97% -$25M 0.01% 254
2022
Q1 		$29.8M Buy
105,086
+45,994
+78% +$14.2M 0.33% 99
2021
Q4 		$22.3M Sell
59,092
-25,334
-30% -$9.84M 0.27% 146
2021
Q3 		$34.8M Sell
84,426
-6,342
-7% -$2.63M 0.48% 62
2021
Q2 		$33.6M Sell
90,768
-16,563
-15% -$5.53M 0.47% 71
2021
Q1 		$31.1M Sell
107,331
-11,502
-10% -$3.2M 0.47% 77
2020
Q4 		$29.7M Sell
118,833
-5,777
-5% -$1.38M 0.49% 69
2020
Q3 		$28.2M Buy
124,610
+5,921
+5% +$1.23M 0.53% 58
2020
Q2 		$20.7M Sell
118,689
-69,611
-37% -$11.1M 0.39% 101
2020
Q1 		$23.8M Sell
188,300
-1,068
-0.6% -$160K 0.6% 52
2019
Q4 		$28.9M Buy
189,368
+280
+0.1% +$38.8K 0.61% 56
2019
Q3 		$25M Buy
189,088
+48,494
+34% +$6.5M 0.57% 60
2019
Q2 		$19.9M Buy
140,594
+3,387
+2% +$459K 0.42% 90
2019
Q1 		$19.9M Buy
137,207
+3,979
+3% +$523K 0.48% 85
2018
Q4 		$15.1M Sell
133,228
-19,252
-13% -$2.41M 0.41% 89
2018
Q3 		$20.5M Buy
152,480
+9,123
+6% +$1.13M 0.52% 77
2018
Q2 		$16.1M Buy
143,357
+136,820
+2,093% +$14.8M 0.46% 86
2018
Q1 		$698K Sell
6,537
-991
-13% -$107K 0.02% 218
2017
Q4 		$824K Buy
7,528
+69
+0.9% +$7.51K 0.03% 212
2017
Q3 		$806K Sell
7,459
-649
-8% -$66.7K 0.03% 225
2017
Q2 		$820K Buy
8,108
+368
+5% +$33.9K 0.03% 201
2017
Q1 		$697K Buy
7,740
+3,095
+67% +$263K 0.03% 219
2016
Q4 		$354K Sell
4,645
-178
-4% -$13.5K 0.02% 250
2016
Q3 		$402K Sell
4,823
-311
-6% -$26.1K 0.02% 251
2016
Q2 		$423K Buy
+5,134
New +$423K 0.03% 244

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Clark Capital Management Group's CRL Position: Q2 2026 in Review

Clark Capital Management Group increased its Charles River Laboratories (CRL) stake by 17% in Q2 2026, buying an estimated $2.66M and bringing the position to 101,462 shares worth $23M. The position accounts for 0.13% of the portfolio, ranked #155.

Clark Capital Management Group first reported a position in CRL in Q2 2016 and has held it in 30 quarters since. The position peaked at $34.8M in Q3 2021. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Clark Capital Management Group held 101,462 shares of Charles River Laboratories worth $23M as of Q2 2026.
  • Clark Capital Management Group bought 14,953 Charles River Laboratories shares in Q2 2026, an estimated $2.66M.
  • Charles River Laboratories made up 0.13% of Clark Capital Management Group's portfolio in Q2 2026, its #155 holding.
  • Clark Capital Management Group first reported a position in Charles River Laboratories in Q2 2016 and has held it in 30 quarters since.
  • Clark Capital Management Group's Charles River Laboratories position peaked at $34.8M in Q3 2021.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Clark Capital Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.